| Active substance | Blinatumomab |
| Holder | Amgen |
| Status | Closed |
| Indication | adults with B-precursor acute lymphoblastic leukemia (ALL) in complete hematological remission defined as less than or equal to 5% blasts in the bone marrow after at least three intense chemotherapy blocks and presence of minimal residual disease (MRD) at a level ≥ 10-4 |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 04/05/2021 |
Blincyto®
Last updated on 04/05/2021